8-K
filed February 22, 2024, 6:59 PM ET
ticker PTHS
CIK 0001919246
other material
confidence high
sentiment positive
materiality 0.80
Chromocell Therapeutics prices IPO at $6.00/share, raises $6.6M gross, lists on NYSE American
Pelthos Therapeutics Inc.
- Sold 1,100,000 shares at $6.00; gross proceeds ~$6.6M; closed Feb 21, 2024.
- Effected 9:1 reverse stock split; amended charter and bylaws effective Feb 15, 2024.
- Underwriter granted 55,000-share warrant at $7.50 (125% of IPO price), exercisable from Aug 2024 to Feb 2029.
- Selling stockholders registered up to 2,969,823 shares for resale; Company receives no proceeds from those sales.
- Net proceeds earmarked for CC8464 studies, eye pain/neuropathic pain trials, Phase 2a Erythromelalgia study, spray-formulation development, and promissory note repayment.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Pelthos Therapeutics Inc.: Amended and Restated By-laws became effective on February 15, 2024, in connection with the pricing of the Initial Public Offering (effective 2024-02-15).
- Change
- bylaw amendment
- Effective
- 2024-02-15
Exact text from the filing
On February 15, 2024, the Company’s Amended and Restated By-laws (the “Restated By-laws”) became effective in connection with the pricing of the Initial Public Offering.
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Pelthos Therapeutics Inc.: Filed amended and restated certificate of incorporation effective upon pricing of Initial Public Offering on February 15, 2024, including a 1-for-9 reverse stock split (effective 2024-02-15).
- Change
- charter amendment
- Effective
- 2024-02-15
Exact text from the filing
On February 15, 2024, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the pricing of the Initial Public Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Pelthos Therapeutics Inc. entered into Underwriting Agreement with A.G.P./Alliance Global Partners (effective 2024-02-15).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- A.G.P./Alliance Global Partners
- Effective
- 2024-02-15
Exact text from the filing
On February 15, 2024, Chromocell Therapeutics Corporation, a Delaware corporation (the “Company”) entered into an underwriting agreement, as amended by that certain Letter Agreement, dated February 16, 2024 (together, the “Underwriting Agreement”) with A.G.P./Alliance Global Partners, as the representative of the underwriters named therein (the “Representative” or, the “Underwriter”), relating to the issuance and sale by the Company to the Underwriter (the “Initial Public Offering”) of an aggregate of 1,100,000 shares (the “Shares”) of the Company’s common stock
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.